news & events

Poster presentations during the EMIM 2024 in Porto

Poster presentations during the EMIM 2024 in Porto

During the annual European Molecular Imaging Meeting (EMIM) in Porto, nine researchers of the Immune-Image consortium presented their promising research during the poster presentations. In this article, we will give a brief summary of each presentation. Identification...

The Immune-Image patient panel

The Immune-Image patient panel

Managing expectations: an insight in the perspective of patients, patient advocates and caregivers on the ideal setup of the Immune-Image patient panel Adding an extra perspective: the patients One important aspect of large European consortia projects such as...

Checkpoint inhibitors and their role in the Immune-Image project

Checkpoint inhibitors and their role in the Immune-Image project

The immune system is our body's natural defense mechanism against diseases, including cancer. It has evolved to recognize and eliminate abnormal cells before they can cause harm. However, cancer cells often find ways to evade the immune system's attacks, allowing them...

Optical Imaging in relation to the Immune-Image Project

Optical Imaging in relation to the Immune-Image Project

The Immune-Image project is a cutting-edge research effort that aims to develop innovative imaging techniques for visualizing immune responses in vivo. The project utilizes a variety of imaging modalities, including PET, MRI, and optical imaging, to gain insights into...

Personalized Medicine and the Immune-Image Project

Personalized Medicine and the Immune-Image Project

Personalized medicine is an approach to healthcare that seeks to provide tailored treatment based on an individual’s unique characteristics, including their genetic makeup, lifestyle, and environmental factors. This approach is becoming increasingly important in the...

PET Imaging: A powerful tool for the Immune-Image project

PET Imaging: A powerful tool for the Immune-Image project

Positron Emission Tomography (PET), is a powerful imaging technique that allows researchers to study the activity of cells and tissues within the body. This imaging modality has been widely used in the medical field to diagnose and monitor a variety of diseases,...

Immune-Image explores a new strategy for imaging CAR-T Cells

Immune-Image explores a new strategy for imaging CAR-T Cells

CAR-T cells, or chimeric antigen receptor T cells, are a type of immunotherapy that has shown great success in treating a subset of blood cancers. In this therapy, the patient’s own cells are genetically modified to recognize and target specific proteins on cancer...

Interview Andreas Jacobs – Leader work package 5

Interview Andreas Jacobs – Leader work package 5

Andreas Jacobs from the University of Münster is leading work package 5 of the Immune-Image project together with Michael Schäfers of the Univerity of Münster and Ian Wilson of ImaginAb. In this work package they research the implementation of immunotracers for...

Meet the partner: ttopstart

Meet the partner: ttopstart

Sigrid van Dorp is working as a consultant at ttopstart and has a background in public health and healthcare management. Within the Immune-Image project, ttopstart is part of work package 1 which focuses on management, coordination, dissemination and sustainability....

18th European Molecular Imaging Meeting (EMIM) in Salzburg

18th European Molecular Imaging Meeting (EMIM) in Salzburg

EMIM 2023 From 14-17 March the 18th European Molecular Imaging Meeting (EMIM) will take place in the world-famous Mirabell park gardens in the heart of Salzburg, the city of Mozart. The focus will be on quantification in molecular imaging, cellular imaging, x-ray/lung...

Interview Manfred Kneilling

Interview Manfred Kneilling

Manfred Kneilling from the University of Tübingen is leading work package 4 of the Immune-Image project together with Bastian Zinnhardt from Roche. In this work package they evaluate the specificity and suitability of new immunotracers targeting different immune cells...

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.